Hundreds of millions of people around the world choose to smoke, despite the well-known health risks. We are passionate about our tobacco business and pride ourselves on offering consumers a choice of high-quality products and market-leading innovations that meet their needs.
We are also extending that choice by developing innovative tobacco and nicotine products that provide consumers with a choice of potentially less risky alternatives to smoking regular cigarettes. We call them Next Generation Products (NGPs) and they include Vapour Products like e-cigarettes, Tobacco Heating Products and nicotine products that are licensed as medicines.
We have invested more than £500 million over five years in developing a world-leading portfolio of products in the NGP category – not just because they are an exciting new opportunity for us, but also because there are clear benefits for society in helping reduce smoking-related disease.
We believe we are best placed to do this because we understand consumer needs, we have world-class R&D
capabilities and robust product and quality standards. We also have global reach and a clear commitment to market our products responsibly.